Introduction
The period from 2024 to early 2025 has witnessed significant updates in hypertension management guidance from both China and the United States. China released comprehensive updates through the Clinical Practice Guideline for the Management of Hypertension in China (2024) published by the Chinese Society of Cardiology and China Hypertension League12, while the United States issued the 2025 AHA/ACC High Blood Pressure Guideline, representing the first major revision since 2017233551. This review synthesizes these contemporary guidelines, focusing on first-line antihypertensive therapy recommendations and blood pressure targets, with emphasis on clinically meaningful differences between the two regional approaches.
Guideline Documents Analyzed
China: The primary source is the Clinical Practice Guideline for the Management of Hypertension in China (doi:10.1097/CM9.0000000000003431)1, issued collaboratively by the Chinese Society of Cardiology and Chinese Hypertension League in 2024, with implementation highlights published in Hypertension Research (pmid:39762483)2. These documents represent the current national standard for hypertension management in China.
United States: The 2025 AHA/ACC/AANP/AAPA/AMA Guideline for High Blood Pressure in Adults published in Circulation and Journal of the American College of Cardiology2326353851, released in 2025, serves as the authoritative US reference. This guideline replaces the 2017 ACC/AHA High Blood Pressure Clinical Practice Guideline and incorporates evidence accumulated through February 202551.
Blood Pressure Diagnostic Thresholds: A Fundamental Divergence
The most striking difference between China and US guidance lies in the diagnostic threshold for hypertension itself. China maintains the traditional threshold of systolic blood pressure (SBP) ≥140 mmHg and/or diastolic blood pressure (DBP) ≥90 mmHg for hypertension diagnosis12. The Chinese guideline introduces a "prehypertension" category defined as SBP 130–139 mmHg and/or DBP 80–89 mmHg, serving as a risk-stratification intermediate category rather than a diagnostic classification of hypertension per se1.
In contrast, the 2025 ACC/AHA guideline sustains the 2017 lowered threshold of ≥130/80 mmHg as the formal definition of hypertension3451. This definitional difference has profound epidemiologic and public health implications: the US framework classifies substantially more individuals as hypertensive and potentially eligible for pharmacotherapy compared to the Chinese system.
Treatment Initiation Criteria: Risk-Stratified Approaches
Both guidelines employ risk-stratified approaches to treatment initiation, but with different triggering thresholds.
China 2024 provides a three-scenario framework1:
- Immediate pharmacotherapy (1B evidence): BP ≥140/90 mmHg
- Recommended initiation (1B evidence): BP 130–139/80–89 mmHg with clinical comorbidities
- Optional initiation (2C evidence): BP 130–139/80–89 mmHg with target organ damage or ≥3 cardiovascular risk factors
For individuals with BP 130–139/80–89 mmHg and 0–2 cardiovascular risk factors, the Chinese guideline recommends lifestyle intervention for 3–6 months first; if BP remains elevated, antihypertensive drug treatment can be considered (2C evidence)1.
The 2025 ACC/AHA guideline represents a significant expansion of treatment recommendations compared to 2017. It now recommends antihypertensive therapy initiation among adults with stage 1 hypertension (BP 130–139/80–89 mmHg) and low 10-year cardiovascular disease risk (<7.5%)4951. This change newly identifies an additional 26.8 million US adults for potential pharmacologic therapy48.
The US approach is notably more aggressive in treating lower-risk individuals at the 130–139/80–89 mmHg range, whereas China maintains a more conservative stance requiring comorbidities or multiple risk factors before initiating pharmacotherapy in this BP range.
Blood Pressure Treatment Targets: Convergence at <130/80 mmHg
Despite different diagnostic thresholds, both guidelines have converged on intensive BP targets for most patients, particularly those at elevated cardiovascular risk.
China 2024 specifies a target of <130/80 mmHg for most adults <65 years with uncomplicated hypertension (2B evidence), as well as for high-risk groups including those with atrial fibrillation (2C), coronary heart disease (2B), heart failure (2B), diabetes mellitus, and history of stable stroke (1A evidence)1. Age-based modification is evident: adults aged 65–79 years maintain the <130/80 mmHg target, while those ≥80 years who tolerate treatment well are assigned a target of 130–139 mmHg1.
The 2025 ACC/AHA guideline establishes a universal BP treatment goal of <130/80 mmHg for all adults on antihypertensive therapy26283551. This represents sustained commitment to the intensive BP control paradigm introduced in 2017, now reinforced by additional evidence accumulated since that time34. The guideline emphasizes that the ≥130/80 mmHg threshold established in 2017 has been strengthened by evidence over the past eight years34.
This target alignment at <130/80 mmHg for most patients represents a key area of international consensus, driven by landmark trials such as SPRINT demonstrating cardiovascular benefit with intensive BP lowering. However, China maintains more explicit age-based target stratification, whereas the US guideline's "universal" target allows for individualized considerations without specifying distinct numerical goals by age category in the primary recommendations captured in the retrieved materials.
First-Line Antihypertensive Agents: Consistency with Nuanced Differences
Both guidelines endorse the same core drug classes as first-line therapy but with subtle positioning differences.
China 2024 recommends ACE inhibitors, ARBs, calcium-channel blockers (CCBs), and diuretics as first-line therapy (1B evidence) for hypertensive patients without clinical complications1. Notably, beta-blockers are explicitly not recommended as first-line agents for uncomplicated hypertension based on comparative efficacy and safety data1. This represents a clear hierarchical positioning among drug classes.
The 2025 ACC/AHA guideline endorses ACE inhibitors (ACEi), angiotensin receptor blockers (ARBs), calcium channel blockers (CCBs), and thiazide/thiazide-like diuretics as first-line agents5052. The search results confirm these four classes are universally endorsed across major international guidelines50, but explicit class-of-recommendation designations (Class I, IIa, IIb) for each drug class in stage-stratified scenarios were not fully captured in the retrieved materials, limiting detailed comparison of recommendation strength.
Both guidelines share consensus on the primacy of renin-angiotensin system inhibitors (RASI), CCBs, and diuretics, with effective demotion of beta-blockers from routine first-line use in uncomplicated hypertension—a position solidified over the past decade based on meta-analytic evidence showing less favorable outcomes compared to other first-line classes.
Combination Therapy Strategies: China's Explicit Preference for Single-Pill Combinations
China 2024 provides clear, proactive guidance on combination therapy. For patients with BP ≥140/90 mmHg, a combination of antihypertensive drugs is initially recommended (1B evidence)1. Critically, single-pill combinations (SPCs) are recommended as priority (2C evidence) when combination therapy is needed1. Preferred dual-therapy pairings include:
- RASI (ACE inhibitor or ARB) + CCB (2C evidence)
- RASI + diuretic (thiazide) (2C evidence)1
This represents a paradigm shift toward earlier, simplified combination therapy to accelerate BP control and improve adherence through reduced pill burden.
The 2025 ACC/AHA guideline distinguishes treatment intensity by stage. For stage 1 hypertension, initiation with a single agent is generally recommended, with subsequent titration of dose or addition of another medication to achieve target BP4751. The specific criteria for monotherapy versus dual therapy initiation, preferred combination pairings, and explicit single-pill combination protocols were not fully detailed in the retrieved search summaries, though the guideline text is expected to address these.
China's explicit prioritization of single-pill combinations and recommendation for combination therapy at the ≥140/90 mmHg threshold reflects pragmatic recognition that most hypertensive patients will ultimately require multiple agents, and starting with rational combinations may improve treatment efficiency and real-world adherence.
Treatment Pathway Practicalities: Monitoring and Follow-Up
China 2024 emphasizes initiating at lower doses in elderly or frail patients and adjusting gradually as tolerated to minimize hypotension risk1. The guideline introduces validated smart wearable devices for hypertension screening and monitoring as an innovation in the 2024 update2, reflecting technological integration into chronic disease management.
The 2025 ACC/AHA guideline specifies that following initial BP evaluation and therapy initiation, follow-up should occur within 2–3 months to assess medication response and adherence3546. Adults with uncontrolled hypertension on new or intensified therapy should have follow-up evaluations for both adherence assessment and therapeutic efficacy46.
Both guidelines emphasize the importance of structured follow-up, though specific electrolyte and renal function monitoring schedules were not comprehensively detailed in the retrieved guideline summaries. Standard clinical practice typically includes monitoring serum potassium and creatinine when initiating RASI or diuretics, with intervals determined by baseline renal function and drug combinations.
Key Differences and Their Drivers
The principal divergence—China's 140/90 mmHg diagnostic threshold versus the US 130/80 mmHg threshold—likely reflects multiple factors:
-
Epidemiologic priorities: China faces a particularly high stroke burden, and the 140/90 threshold aligns with historical stroke prevention trial data. The US emphasis on comprehensive cardiovascular disease prevention (including myocardial infarction and heart failure) motivates the lower threshold.
-
Healthcare system capacity: China's large population and healthcare resource distribution may favor a higher diagnostic threshold to focus pharmacotherapy on higher-risk individuals, while lifestyle intervention is emphasized for the 130–139/80–89 mmHg prehypertension category1.
-
Evidence interpretation: Both guidelines cite overlapping trial evidence (SPRINT, etc.), but differ in threshold-setting based on risk-benefit assessment, with the US adopting a more preventive stance for lower-risk populations at stage 1 BP levels49.
-
Treatment targets versus diagnostic thresholds: Importantly, both guidelines converge on <130/80 mmHg as the treatment target for most patients, indicating shared recognition of the benefit of intensive BP lowering once therapy is initiated.
What Is Genuinely New in 2024–2025
China 2024:
- Formal endorsement of smart wearable devices for screening and monitoring2
- Emphasis on low-sodium, potassium-rich salt substitutes and Chinese heart-healthy diet recommendations2
- Inclusion of sleep and mental health management in lifestyle modifications2
- Specific attention to morning hypertension and nocturnal hypertension phenotypes requiring tailored management2
US 2025 ACC/AHA:
- Expansion of treatment recommendations to stage 1 hypertension with low CVD risk (<7.5%), identifying 26.8 million additional adults for therapy consideration4849
- Introduction of the PREVENT equation to replace the Pooled Cohort Equation for 10-year cardiovascular risk calculation, refining risk stratification for treatment decisions2433
- Conceptual shift emphasizing "risk management" rather than isolated BP reduction, integrating comprehensive cardiovascular risk assessment into treatment planning33
Clinical Implications and Conclusions
The 2024–2025 hypertension guideline updates from China and the US demonstrate both convergence and persistent divergence. Treatment targets have aligned at <130/80 mmHg for most patients, reflecting shared interpretation of intensive BP-lowering trials. First-line drug classes remain consistent (RASI, CCB, diuretics), with both regions de-emphasizing beta-blockers for uncomplicated hypertension.
However, diagnostic thresholds remain distinct (China 140/90 vs US 130/80 mmHg), and treatment initiation strategies differ in their approach to lower-risk individuals with BP in the 130–139/80–89 mmHg range. China's explicit prioritization of single-pill combinations and recommendation for combination therapy at BP ≥140/90 mmHg represents a more structured, proactive approach to achieving BP control efficiently.
For the global clinician, these guidelines underscore that while international consensus exists on many core hypertension management principles, local context—including population risk profiles, healthcare infrastructure, and resource availability—appropriately shapes specific threshold and treatment-initiation decisions. The emphasis in both guidelines on individualized therapy, monitoring, and adherence support reflects the reality that optimal hypertension management requires more than protocol adherence; it demands patient-centered application of evidence-based targets and therapies13551.